Articles tagged with Tumor Cells
Researchers discovered that melanoma skin cancer cells adopt an efficient style of movement called rounded-amoeboid migration, which requires less energy than traditional cell movement. This process involves reshaping mitochondria to operate in a low-power mode, allowing cells to survive in stressful environments.
A research team at Göttingen University has discovered that mobile and stationary cells have different mechanical properties due to their cytoskeleton. The study found that intermediate filaments, which are crucial for cell stability, exhibit metal-like plasticity when stretched, similar to non-biological materials.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Research reveals that brain tumor cells communicate with astrocytes through microtubes, transferring mitochondria to enhance growth. This connection increases treatment resistance and tumorigenicity in glioblastoma tumors.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
A clinical trial of 406 patients found that a fluorescent agent allowed surgeons to identify and remove residual tumor tissue with favorable results. The technique showed promising results in detecting tumor tissue missed by standard lumpectomy procedures, potentially avoiding second surgeries for positive margins.
Researchers developed glass filters to capture tumor cells from blood samples, enabling more efficient culture of these cells. The optimized filter design enhances the accuracy of cancer detection, allowing for earlier treatment and improved patient health.
A novel cell signaling pathway has been identified that could be targeted to treat aggressive pancreatic cancers. The High Mobility Group A1 (HMGA1) protein functions as a 'molecular switch' that activates genes required for tumor growth and invasion. Silencing HMGA1 or disrupting FGF19 signals in mouse models resulted in decreased tum...
A study of 5,000 patients with breast cancer found that women from disadvantaged neighborhoods had shorter breast cancer-specific survival rates compared to those from advantaged areas. The findings suggest potential unaccounted mechanisms, including social determinants of health and access to care.
Tumors with low PD-L1 levels use genetic strategies like MYC activation to avoid immune attack, but this can be predicted by monitoring for MYC status. The study's findings could lead to new clinical trials assessing MYC status as a marker for selecting patients for immunotherapy.
Scientists discovered that deleting a protein called sphingosine kinase 2 (SphK2) reprograms the tumor microenvironment, decreasing S1P levels and increasing p53 tumor suppressor gene accumulation. This creates an inhospitable environment for aggressive breast tumors.
Researchers develop mechanical nanosurgery to destroy tumour cells from within, reducing GBM tumour size universally, including in TMZ-resistant cases. The treatment uses magnetically controlled carbon nanotubes to provide mechanical stimulation, damaging cellular structures and causing tumour cell death.
A new nuclear medicine therapy has been shown to cure human non-Hodgkin lymphoma in an animal model, achieving a median survival of over 221 days. The treatment, [177Lu]Lu-ofatumumab, was found to quickly eliminate tumor cells and showed favorable in vitro characteristics.
Researchers found that neutrophils activated by T cell-based immunotherapy can kill tumor cells that evade targeted therapies. This unexpected antitumor response could lead to new immunotherapies that harness this potent immune mechanism.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Research at IRB Barcelona reveals CPEB4's essential role in T lymphocytes' adaptation to chronic cellular stress. By overcoming this stress, these cells can exert their antitumour function and halt tumour growth.
A new technique combines machine learning with short-wave infrared fluorescence imaging to detect precise tumor boundaries with higher accuracy than traditional methods. The approach achieved a remarkable per-pixel classification accuracy of 97.5 percent and demonstrated robustness against changes in imaging conditions.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
A team of researchers has discovered a simple way to deliver cancer therapeutics to tumor cells by fluidizing the cell membrane using lipid nanoparticles containing EDTA. The mechanism is independent of metal chelation properties and involves changing the characteristics of the cell membrane to promote nanoparticle uptake.
A study found that Spp24 inhibits osteosarcoma tumor cell proliferation, invasiveness, and promotes apoptosis. It achieves this by neutralizing bone morphogenetic protein 2.
Tumour cells exhibit an innate randomness in their ability to respond to chemotherapy, which can lead to resistance. Researchers identified a marker for resistance and propose combining chemotherapy with drugs targeting this 'noise' to improve treatment outcomes.
Researchers developed a new device that detects and analyzes cancer cells in blood samples, enabling doctors to avoid invasive biopsies and monitor treatment progress. The Static Droplet Microfluidic device uses metabolic signatures to differentiate tumour cells from normal blood cells.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
Researchers have discovered that inhibiting conventional signalling pathway by disrupting LCK allows more efficient tumour cell killing, using FYN protein instead. This approach enhances T-cell function and reduces graft-versus-host disease, making CAR-T therapy more accessible to patients.
Researchers developed a cancer-selective therapeutic agent that targets cancer cells' unique acidic pH microenvironment, inducing mitochondrial dysfunction and killing only cancer cells. The agent, Mito-SA, forms charge-shielded nano-assemblies that selectively disassemble in the tumoral environment.
Researchers analyzed tumor microenvironment of pancreatic cancer, revealing two major defects that inhibit immune response. The study suggests a new approach using anti-CD137 agonist antibody treatment in combination with anti-PD-1 immunotherapy to activate T cells.
Researchers discover that tumour tracks, formed by transformed blood vessels, trap immune cells and promote healing processes. The tension of extracellular matrix fibers plays a key role in tumour development, allowing cancer cells to grow undisturbed.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Researchers at Brigham and Women's Hospital have developed a dual-action cell therapy approach to eliminate established tumors and induce long-term immunity. The vaccine, engineered using CRISPR-Cas9, is designed to kill tumor cells and stimulate the immune system to destroy primary tumors and prevent cancer recurrence.
Researchers tracked 392 patients with diffuse low-grade glioma over 20 years and found that aggressive surgical removal offered a distinct survival advantage. Smaller tumor sizes were associated with longer survival times, highlighting the importance of early intervention.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers at Tulane University discovered that breast cancer cells use complex immune-modulatory programs to evade immune clearance, leading to treatment resistance. They identified 16 immune checkpoint genes and found that chemotherapy triggers a program of immune checkpoints that shield cancer cells from different lines of attack.
The TIL trial has demonstrated that cell therapy using patient's own immune cells is an extremely powerful immunotherapy for metastatic melanoma, with significant shrinkage of metastases in half of patients. Progression-free survival after six months was 53%, significantly better than standard immunotherapy with ipilimumab.
Researchers found that tumor cells directly interact with blood vessel cells, altering their normal clockwise orientation to a counterclockwise position. This interaction may play a role in cancer metastasis and could be targeted for prevention and treatment.
Kevin McHugh, a Rice bioengineer, has received the Distinguished Scientist Award from The Sontag Foundation for his work on gene editing to defeat glioblastoma multiforme. His approach involves delivering gene therapy agents directly to tumor cells, aiming to improve survival and reduce side effects.
Comprehensive metabolic changes convert mature liver cells into immature progenitor cells that proliferate rapidly and develop tumors. The main causes of liver cancer are metabolic disorders and infections with hepatitis C virus and high alcohol consumption.
Researchers at Goethe University Frankfurt found that dying colon cancer cells release ATP to neighboring tumor cells, activating a survival signaling pathway. Interrupting this communication can significantly increase the effectiveness of chemotherapy against resistant tumors.
A new study reveals that the protein fragile X mental retardation protein (FMRP) plays a crucial role in helping tumors evade immune destruction, leading to treatment resistance. FMRP regulates a network of genes and cells in the tumor microenvironment, contributing to its ability to hide from immune cells.
Neuroblastoma tumour cells adapt to mimic embryonic cells, making them resistant to chemotherapy. This understanding can lead to targeted treatments that better reach the entire tumour and avoid resistance development.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers at IRB Barcelona have identified the tiny fraction of tumour cells that remain hidden after surgery, leading to metastatic recurrence. These 'High Relapse Cells' can be eliminated through genetic techniques, preventing metastases and opening the possibility for new therapeutic strategies.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
Researchers used DNA barcoding to track breast cancer cells over time, finding that some cells can suppress killer T-cells and reduce MHC1 expression to evade the immune system. This study suggests epigenetic mechanisms may play a role in cancer cell adaptation and provides potential targets for therapies.
Researchers at VCU Massey Cancer Center have found strong evidence for testing a novel drug in liver cancer treatment. MDA-9 inhibition may be an effective approach for hepatocellular carcinoma (HCC), with potential synergies with other therapeutics.
A new method of modifying our immune system has been demonstrated in a study published in Advanced Science, which could help treat skin cancer.
Filopodia contribute to building a barrier surrounding breast tumours, blocking their escape. Cancer cells lacking Myosin-10 cannot maintain this barrier, making it easier for them to spread.
A new study suggests that chlorhexidine gluconate (CHG) is the most effective irrigation solution for killing bone tumor cells after surgery. CHG shows highest cytotoxicity against chondrosarcoma and giant cell tumors, potentially making it a useful chemical adjuvant during intralesional curettage.
Researchers at the University of Seville have discovered a method to attack cancer cells using an origin-of-life molecule. The study found that inhibiting RNA production boosts the utility of radiation therapy in cancer cells, offering a promising approach to treating various types of cancer.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
A gene signature of four specific genes (SAA1, SAA2, APOL1, and MET) predicts the risk of tumour spreading and survival in kidney cancer patients. The study identified a link between the microenvironment and immune system inhibition.
Researchers at Mount Sinai's Tisch Cancer Institute have discovered a new gene, PDZK1IP1, essential to colon cancer growth. The study found that surrounding inflammation activates the super enhancer, promoting tumor cell survival and growth.
Recruitment of tumor-fighting macrophages depends on testosterone. Administering testosterone to females increases macrophage ability to eradicate tumor cells.
Researchers developed a low-cost, simple imaging system using tumor-targeting fluorescent molecules to determine tumor depth. The portable system provides quantitative information about the depth of tumor cells in the body, helping surgeons remove healthy tissue around tumors for better outcomes.
A team of 15 doctoral researchers is investigating targeted cancer treatments by developing special molecules that stimulate the immune system to destroy tumor cells. These minimally invasive anti-cancer drugs attach a substance that damages tumor tissue to a transporter molecule, recognizing and delivering it to cancerous cells.
A study published in Science reveals that tumor cells with a specific mutation release a chemical metabolite that weakens nearby immune cells, rendering them less capable of killing cancer cells. The findings highlight the critical role of the tumor microenvironment in cancer growth and provide insights into developing targeted therapi...
Researchers have developed a new approach to test the efficacy of multiple anticancer drug combinations simultaneously, rapidly, and accurately. Combi-seq overcomes limitations of conventional technologies by using microfluidics to carry out large-scale experiments with small sample volumes.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
Research reveals that tumor cells form temporary structures to avoid destruction by the immune system. The findings suggest that timed inhibition of relevant signaling pathways is necessary alongside immunotherapy to prevent tumor resistance.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.